Previous 10 | Next 10 |
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Certain immaterial corrections have been made to the second and fifth paragraphs. ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manu...
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the hea...
ImmuCell (NASDAQ:ICCC) released its first quarter estimates on Monday with revenue up 46% Y/Y to $6M due to supply ease and higher production capacity. The company's CEO Michael F. Brigham told, "this favorable comparison does reflect tighter supply constraints during the first quarter o...
PORTLAND, Maine, April 11, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the h...
ImmuCell Corp (ICCC) Q4 2021 Earnings Conference Call February 23, 2022, 9:00 AM ET Company Participants Michael Brigham – President, Chief Executive Officer Joe Diaz – Lytham Partner Betsy Williams – Vice President of Manufacturing Operations Bobbi Jo Brockmann – ...
ImmuCell press release (NASDAQ:ICCC): FY GAAP EPS of -$0.01 beats by $0.10. Revenue of $19.24M (+25.8% Y/Y) beats by $2.59M. For further details see: ImmuCell GAAP EPS of -$0.01 beats by $0.10, revenue of $19.24M beats by $2.59M
PORTLAND, Maine, Feb. 22, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the he...
PORTLAND, Maine, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
PORTLAND, Maine, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
ImmuCell Corp (ICCC) Q3 2021 Earnings Conference Call November 16, 2021, 09:00 ET Company Participants Joe Diaz - Lytham Partner Michael Brigham - President, CEO, Principal Financial Officer, Treasurer, Secretary & Director Conference Call Participants Scott Billeadeau - Walrus Partners P...
News, Short Squeeze, Breakout and More Instantly...
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the he...
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health an...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...